Get the Stockscreener App
1.20
0.83%
-0.01
Pre-market:
1.29
0.09
+7.50%
Actinium Pharmaceuticals Inc stock is traded at $1.20, with a volume of 259.50K.
It is down -0.83% in the last 24 hours and down -22.58% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.21
Open:
$1.18
24h Volume:
259.50K
Relative Volume:
0.46
Market Cap:
$41.18M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-0.6557
EPS:
-1.83
Net Cash Flow:
$-47.49M
1W Performance:
-9.09%
1M Performance:
-22.58%
6M Performance:
-32.58%
1Y Performance:
-82.48%
1-Day Range:
$1.165
$1.21
1-Week Range:
$1.165
$1.34
52-Week Range:
$1.06
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.20 | 41.18M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Actinium Pharmaceuticals, Inc. Class Action: Levi & - GlobeNewswire
Actinium Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Actinium Investors of - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - TradingView
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM)May 27, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire
ATNM INVESTORS: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TradingView
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Actinium - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
Actinium Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. LawsuitATNM - MarketScreener
Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Upgraded by StockNews.com - Defense World
The Gross Law Firm Reminds Actinium Pharmaceuticals, Inc. - GlobeNewswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. LawsuitATNM - PR Newswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Actinium Pharmaceuticals, Inc. Investors: Please contact - GlobeNewswire
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm - The Malaysian Reserve
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
Actinium Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 27, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. - GlobeNewswire
The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit - Bluefield Daily Telegraph
ATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the Class - PR Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
Sei Investments Co. Invests $62,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium LawsuitATNM - PR Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATNM - Morningstar
Lawsuit filed for Investors who lost money with shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - openPR.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATNM - ACCESS Newswire
The Gross Law Firm Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
Actinium Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM - PR Newswire
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Target Price from Analysts - Defense World
Shareholders of Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM - ACCESS Newswire
ATNM Stockholders Should Contact Robbins LLP for Information on How to Lead the Class Action Against Actinium Pharmaceuticals, Inc. - PR Newswire
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class ActionATNM - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders - ACCESS Newswire
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):